Published in Front Biosci (Landmark Ed) on January 01, 2009
Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal (2010) 1.53
A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab (2015) 1.09
Nuclear receptors in bile acid metabolism. Drug Metab Rev (2013) 1.02
Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis. Semin Liver Dis (2010) 0.93
Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations. Mol Aspects Med (2013) 0.85
Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s. Drug Metab Dispos (2013) 0.85
Pleiotropic functions of the organic solute transporter Ostα-Ostβ. Dig Dis (2011) 0.82
Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective. Drug Metab Rev (2012) 0.81
Transcriptional regulation of the intestinal nuclear bile acid farnesoid X receptor (FXR) by the caudal-related homeobox 2 (CDX2). J Biol Chem (2014) 0.76
HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis. Front Pharmacol (2017) 0.75
MicroRNA-30c-1-3p is a silencer of the pregnane X receptor by targeting the 3'-untranslated region and alters the expression of its target gene cytochrome P450 3A4. Biochim Biophys Acta (2016) 0.75
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab (2005) 9.14
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A (2006) 3.05
Cholesterol gallstone disease. Lancet (2006) 2.83
REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis. PLoS Biol (2009) 2.76
Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology (2011) 2.67
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57
Identification of a hormonal basis for gallbladder filling. Nat Med (2006) 2.03
Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology (2014) 1.68
Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem (2007) 1.62
Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res (2008) 1.61
Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem (2004) 1.57
Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal (2010) 1.53
FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J Lipid Res (2007) 1.31
Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci U S A (2011) 1.23
Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology (2008) 1.22
Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab (2010) 1.20
Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology (2007) 1.20
Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol (2005) 1.16
Down-regulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes. Hepatology (2010) 1.09
The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology (2009) 1.08
Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROME II criteria for irritable bowel syndrome. World J Gastroenterol (2003) 1.03
Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip Rev Syst Biol Med (2011) 1.02
Bile acids and colon cancer: Solving the puzzle with nuclear receptors. Trends Mol Med (2011) 1.01
Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett (2006) 1.01
Gallbladder histopathology during murine gallstone formation: relation to motility and concentrating function. J Lipid Res (2005) 1.00
Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology (2013) 1.00
Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology (2012) 1.00
The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer. PLoS One (2012) 0.98
Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clin Biochem (2007) 0.94
Atherosclerosis: lessons from LXR and the intestine. Trends Endocrinol Metab (2012) 0.87
Non-alcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des (2007) 0.87
Nuclear receptors in regenerating liver and hepatocellular carcinoma. Mol Cell Endocrinol (2012) 0.86
Proteomics for the discovery of nuclear bile acid receptor FXR targets. Biochim Biophys Acta (2011) 0.85
Hepatic-specific activation of peroxisome proliferator-activated receptor γ coactivator-1β protects against steatohepatitis. Hepatology (2013) 0.85
SEL1L, an UPR response protein, a potential marker of colonic cell transformation. Dig Dis Sci (2012) 0.84
Medicinal treatments of cholesterol gallstones: old, current and new perspectives. Curr Med Chem (2009) 0.84
A translational view on the biliary lipid secretory network. Biochim Biophys Acta (2007) 0.84
Pathobiology of cholesterol gallstone disease: from equilibrium ternary phase diagram to agents preventing cholesterol crystallization and stone formation. Curr Drug Targets Immune Endocr Metabol Disord (2003) 0.83
Intestinal ecology in the metabolic syndrome. Cell Metab (2010) 0.83
Neuron-derived orphan receptor 1 promotes proliferation of quiescent hepatocytes. Gastroenterology (2013) 0.82
Impaired gallbladder motility and delayed orocecal transit contribute to pigment gallstone and biliary sludge formation in beta-thalassemia major adults. World J Gastroenterol (2004) 0.82
Fibroblast growth factor 21: a new liver safeguard. Hepatology (2014) 0.82
Parallel intestinal and liver injury during early cholestasis in the rat: modulation by bile salts and antioxidants. Free Radic Biol Med (2007) 0.82
Effect of dietary restriction and N-acetylcysteine supplementation on intestinal mucosa and liver mitochondrial redox status and function in aged rats. Exp Gerontol (2004) 0.82
Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling. Acta Neuropathol (2013) 0.81
Quantitation of cholesterol crystallization from supersaturated model bile. J Lipid Res (2002) 0.81
Effects of hydrophobic and hydrophilic bile salt mixtures on cholesterol crystallization in model biles. Biochim Biophys Acta (2002) 0.79
Improving nonalcoholic fatty liver disease management by general practitioners: a critical evaluation and impact of an educational training program. J Gastrointestin Liver Dis (2008) 0.79
Nuclear receptors expression chart in peripheral blood mononuclear cells identifies patients with Metabolic Syndrome. Biochim Biophys Acta (2013) 0.79
Aminotransferase activity in morbid and uncomplicated obesity: predictive role of fasting insulin. Nutr Metab Cardiovasc Dis (2006) 0.78
Water handling and aquaporins in bile formation: recent advances and research trends. J Hepatol (2003) 0.78
Micellar lipid composition profoundly affects LXR-dependent cholesterol transport across CaCo2 cells. FEBS Lett (2009) 0.77
Targeting the liver in the metabolic syndrome: evidence from animal models. Curr Pharm Des (2007) 0.77
Bax is necessary for PGC1α pro-apoptotic effect in colorectal cancer cells. Cell Cycle (2011) 0.77
Normal serum alanine aminotransferase activity in uncomplicated obesity. World J Gastroenterol (2005) 0.76
Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists. J Med Chem (2009) 0.76
Taurodeoxycholate-induced intestinal injury is modulated by oxidative stress-dependent pre-conditioning like mechanisms. Toxicol Lett (2008) 0.76
Hepatic Niemann-Pick C1-like 1: The canalicular side of the coin. Hepatology (2007) 0.76
Modulation of cholesterol crystallization in bile. Implications for non-surgical treatment of cholesterol gallstone disease. Curr Drug Targets Immune Endocr Metabol Disord (2005) 0.75
Preface: a special issue on nuclear receptors with a special view on the molecular basis of disease. Biochim Biophys Acta (2011) 0.75
The "hemolysis model" for the study of cyto-toxicity and cyto-protection by bile salts and phospholipids. Adv Exp Med Biol (2006) 0.75
From lipid secretion to cholesterol crystallization in bile. Relevance in cholesterol gallstone disease. Ann Hepatol (2004) 0.75